Login to Your Account



Amgen Offers More On Aranesp, Starts Phase III Loading' Trial

By Randall Osborne


Wednesday, May 22, 2002
Girding for a marketplace battle in oncology, Amgen Inc. offered encouraging data regarding its anemia product Aranesp (darbepoetin alfa), approved in September for dialysis and nondialysis patients with chronic liver failure and already being used off-label for cancer patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription